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Abstract
Background: Atopic dermatitis (AD) is one of the most common skin diseases with a 
multifactorial etiology. Mutations leading to loss of skin barrier function are associ‐
ated with the development of AD with group 2 innate lymphoid cells (ILC2) promot‐
ing acute skin inflammation. Filaggrin‐mutant (Flgft/ft) mice develop spontaneous skin 
inflammation accompanied by an increase in skin ILC2 numbers, IL‐1β production, 
and other cytokines recapitulating human AD. Here, we investigated the role of ILC2, 
effector cytokines, inflammasome activation, and mast cell function on the develop‐
ment of chronic AD‐like inflammation in mice.
Methods: Mice with a frameshift mutation in the filaggrin gene develop spontaneous 
dermatitis. Flgft/ft mice were crossed to cell‐ or cytokine‐deficient mouse strains, or 
bred under germ‐free conditions. Skin inflammation was scored, and microbiome 
composition was analyzed. Skin protein expression was measured by multiplex im‐
munoassay. Infiltrating cells were analyzed by flow cytometry.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
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1  | INTRODUC TION
Atopic dermatitis (AD) is a common eczematous pruritic disease 
with an onset at an early age, affecting up to 30% of children in the 
Western world. Etiology of AD is multifactorial including genetic 
predisposition, environmental factors, and immune status, leading 
to a high complexity in clinical presentation.1‐3 Predisposing genetic 
factors for the development of AD include mutations in genes af‐
fecting the integrity of the skin barrier, such as mattrin (TMEM79) 
and filaggrin (filament aggregation protein, FLG).4‐6 Filaggrin muta‐
tions were found in 30% of AD patients in Poland,7 China (26.0%),8 
and Korea (15.7%),9 while healthy individuals had none. Importantly, 
filaggrin expression is downregulated in AD patients independent of 
their FLG genotype as a consequence of increased type 2 cytokines 
contributing to the aggravation of disease.10
We have previously separated and described the two mutated 
genes—Tmem79/mattrin and filaggrin—leading to the allergic skin phe‐
notype of flaky tail mice.5,11 Single mutant mice both have a defective 
skin barrier, and both spontaneously develop AD‐like inflammation. 
Pathogenesis in Tmem79ft/ft mice is dependent on adaptive immunity, 
while Flgft/ft mice develop dermatitis through innate immune cells.11 
However, the mechanisms underlying inflammation are unclear.
Results: Wild‐type and Flgft/ft mice significantly differ in their microbiome composi‐
tion. Furthermore, mutant mice do not develop skin inflammation under germ‐free 
conditions. ILC2 deficiency did not ameliorate chronic dermatitis in Flgft/ft mice, which 
was also independent of IL‐4, IL‐5, IL‐9, IL‐13, IL‐17A, and IL‐22. Inflammation was in‐
dependent of NLRP3 inflammasome activation but required IL‐1β and IL‐1R1‐signal‐
ing. Mechanistically, IL‐1β promoted hyperactivation of IL‐1R1‐expressing mast cells. 
Treatment with anti‐IL‐1β‐antibody alleviated dermatitis exacerbation, while antibi‐
otic intervention ameliorated dermatitis in neonatal mice but not in adults with estab‐
lished inflammation.
Conclusions: In summary, we identified a critical role for the microbiome and IL‐1β 
mediating chronic inflammation in mice with an impaired skin barrier.
K E Y W O R D S
atopic dermatitis, filaggrin, IL‐1β, innate lymphoid cells, microbiome
G R A P H I C A L  A B S T R A C T
Filaggrin deficiency leads to skin dysbiosis early after birth altering adult immune responses, while mice raised under germ‐free conditions 
remain disease‐free. NLR Family Pyrin Domain Containing 3‐independent processing of IL‐1 in the skin promotes atopic dermatitis (AD)‐like 
ILC2‐independent inflammation. IL‐1 deficiency or targeting IL‐1 by monoclonal antibodies ameliorates dermatitis. IL‐1R1‐expressing dermal 
mast cells are key responders to IL‐1, acquire a hyperactive phenotype, and promote AD‐like inflammation.
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As an atopic disorder, AD is classically considered a type 2‐driven 
immunopathology involving type 2 T helper (Th2) cells, interleukin 
(IL)‐4, IL‐5, IL‐9, and IL‐13, as well as IgE, mast cells, basophils, and 
eosinophils—with more recent data expanding this view to include 
Th17 and IL‐22 cellular responses in the genesis of AD.12 While T 
cells are promoting inflammation in certain instances,13‐15 they are 
largely dispensable in the Flgft/ft model. Mast cells have long been 
associated with AD, and increased numbers are found in the skin of 
atopic patients.16 Upon activation by cytokines, FcεRI‐bound IgE, 
or pathogen‐ and danger‐associated molecular patterns, mast cells 
can release large amounts of pro‐inflammatory mediators, such as 
tumor necrosis factor (TNF).17,18 Furthermore, increased numbers 
of group 2 innate lymphoid cells (ILC2) in the skin of Flgft/ft mice and 
patients with mutations in FLG11 suggest a central role for ILC2 in 
genesis of skin inflammation in this model. ILC2 are potent innate 
regulators of type 2 immune responses19‐24 and have been shown 
to promote inflammation in a model of acute dermatitis induced 
by topical application of MC903 (calcipotriol, vitamin D3 ana‐
logue).25‐28 However, their role in spontaneous dermatitis in Flgft/
ft mice is unknown.
Another hallmark of AD is skin dysbiosis, with a shift toward a 
pathogenic microbiome, in which beneficial commensals such as 
Propionibacteria or Staphylococcus epidermidis are displaced by other 
species such as S. aureus, and the patients’ overall skin microbiota di‐
versity decreases.29‐32 Results from flaky tail mice (Flgft/ftTmem79ft/ft) 
suggested that the microbiota promotes upregulation of IL‐17A and 
the infiltration of neutrophils and eosinophils into the skin.33
Polymorphisms in members of the IL‐1 family of cytokines and 
their receptors are associated with skin disorders, such as cutaneous 
lupus erythematosus, psoriasis, and atopic dermatitis.34,35 We have 
previously reported increased IL‐1α, IL‐1β, and IL‐1R1 expression in 
skin of Flgft/ft mice and AD patients with mutations in FLG.36
In the present study, we set out to investigate the mechanisms 
underlying AD‐like inflammation in Flgft/ft mice. We discovered that 
ILC2—while required for acute MC903‐induced dermatitis—were 
dispensable for spontaneous AD‐like inflammation in Flgft/ft mice 
with an impaired skin barrier. Instead, the development of skin in‐
flammation was dependent on an interplay between microbiota, 
IL‐1β, and mast cells.
2  | MATERIAL AND METHODS
2.1 | Mice
The following mice were backcrossed onto the Flgft/ft (initially isolated 
from flaky tail mice, JR#9078, Jackson Laboratories, Bar Harbor, ME11) 
BALB/c background for >8 generations: Rag1−/− (JAX: 002216),37 
Rag2−/−γc−/−38 (JAX; 014593), Il7rCre,39 Roraflox,23 sg/sg mice,40 Il4KN2,41 
Il5cer/cer,11 ll13−/−,42 Il9cit/cit,43 Il17a−/−,44 Il22−/−,45 Nlrp3−/−,46 Il1a−/−,47 
Il1b−/−47, Il1r1−/− (JAX:003245),48 Il18−/− (JAX:004130),49 Asc−/−,50 
Aim2−/−,51 KitW‐sh/W‐sh (JAX:005051),52 and Il36r−/−.53 Mice were housed 
in a specific pathogen‐free facility, with irradiated diet and water ad 
libitum. Experiments under germ‐free conditions were conducted at 
the Instituto Gulbenkian De Ciência in Portugal. Animal experiments 
were approved by Trinity College Dublin BioResources and Instituto 
Gulbenkian de Ciência ethical review board and performed in compli‐
ance with EU Directive 2010/63/EU, Irish Medicine's Board and The 
Health Products Regulatory Authority.
2.2 | Scoring of skin inflammation
Severity of skin inflammation was clinically scored (total range: 0‐12) 
by macroscopic diagnostic criteria as previously described.5 The 
total score is the sum of individual scores ranging from 0 to 3 (0, 
none; 1, mild; 2, moderate; 3, severe) that were applied to edema, 
erythema, scaling, and erosion.
2.3 | Preparation of bone marrow–derived mast 
cells (BMMC) and stimulation
Bone marrow was isolated from the femur and tibia of donor mice and 
cultured in media (RPMI + 10% FBS + L‐glutamine + penicillin/strep‐
tomycin + HEPES + non‐essential amino acids) containing 10 ng/mL 
SCF and 10 ng/mL IL‐3 (R&D systems) for a total of 4 weeks with 
media changes twice a week.54,55 3 × 105 mast cells/well were left 
untreated or were stimulated with plate‐bound anti‐FcεRIα (10 µg/
mL, clone MAR‐1, Thermo Scientific) in the presence or absence of 
IL‐1β (10 ng/mL, R&D systems) for 24 hours. For adoptive transfers, 
BMMC were resuspended in sterile PBS. Mice received 1 × 106 mast 
cells via intradermal injection into the ear.
2.4 | Microbiome analysis
Skin microbiome samples were acquired by exposing sterile swabs 
to the ear skin of Flgft/ft and wild‐type mice, as previously pub‐
lished.56 Mice were kept in the same or adjacent cages, looked 
after by the same person using the same products. Same surface 
area was sampled for all age‐ and sex‐matched mice. To avoid 
cross‐contamination, sterile gloves were changed between each 
sample collected. Samples were instantly frozen in liquid nitro‐
gen, and 16S rRNA gene sequencing and microbiome analysis was 
performed by Second Genome (San Francisco, CA), as previously 
described.57
2.5 | Axenic mouse model generation
Male and female Flgft/ft mice were shipped from Trinity College 
Dublin to the Instituto Gulbenkian De Ciência in Portugal and re‐de‐
rived by embryo transfer from a quarantine facility into SPF housing. 
Subsequent litters were generated by timed‐pregnancies. Fetuses 
were transferred to GF isolators and fostered by GF C3H mothers, 
as described in the relevant EMMA protocol (http://strains.emmane‐
t.org/protocols/GermFree_0902.pdf). Germ‐free and age‐matched 
SPF control litters were raised and maintained under strictly identi‐
cal conditions (food, water, humidity, temperature), except the mi‐
crobiological status.
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2.6 | Statistics
GraphPad Prism (version 7) was used to generate graphs and for 
statistical analysis. Area under curve (AUC), Student's t test, and 
ANOVA were used to determine statistical significance. P‐val‐
ues < 0.05 were considered statistically significant.
Please refer to the Supporting Information for additional mate‐
rials and methods.
3  | RESULTS
3.1 | Flgft/ft mice develop spontaneous atopic 
dermatitis–like skin inflammation
We sought to investigate the innate mechanisms that elicit in‐
flammation in Flgft/ft mice. Flgft/ft mice develop spontaneous skin 
inflammation as neonates, with a second phase of overt inflamma‐
tion—most prominent around the eyes and ears—progressing from 
8 weeks of age evidenced by a constant increase in clinical severity 
(Figure 1A,B). The impaired skin barrier in Flgft/ft mice is represented 
by significantly increased transepidermal water loss (TEWL), and de‐
velopment of skin inflammation is accompanied by increased circu‐
lating IgE (Figure 1C,D). Skin histology of Flgft/ft mice shows dermal 
and epidermal thickening, scaling, and cellular infiltration into the 
skin (Figure 1E). Among skin infiltrating immune cells, we find signifi‐
cantly increased numbers of ILC2, eosinophils, basophils, Th2 cells, 
and also mast cells (Figure 1F)—similar to the localized immune cell 
repertoire in AD patients.11,27,58‐60
3.2 | Pathogenic cutaneous microbiome promotes 
chronic inflammation in Flgft/ft mice
In order to investigate whether Flgft/ft mice faithfully reflect the 
dysbiosis apparent in the skin microbiome of AD patients, we ana‐
lyzed their skin microbiota. 16S rRNA‐sequencing revealed a sig‐
nificantly altered microbiome in both adult and neonatal Flgft/ft mice 
compared to wild‐type animals kept in the same facility (Figure 2A). 
The defective skin barrier integrity in Flgft/ft mice led to decreased 
F I G U R E  1   Flgft/ft mice develop spontaneous atopic dermatitis associated with increased cellular infiltration. A, Representative 
photographs of wild‐type Balb/c (WT, top) and filaggrin‐mutant Flgft/ft mice (bottom) at ten weeks of age. B, Macroscopic clinical scoring 
of Balb/c (black) and Flgft/ft (red). Graph shows the mean ± SEM from 20 mice per group. ***, P < 0.001, t test of AUC. C, Total serum IgE 
concentrations from adult wild‐type (black) and 12‐wk‐old Flgft/ft mice (red). Bars show the mean ± SEM of seven mice. *, P < 0.05. D, 
Transepidermal water loss (TEWL) at 12 wk in wild‐type (black) and Flgft/ft mice (red). Bars show the mean ± SEM of nine mice. *, P < 0.05. E, 
Representative photomicrograph of H&E‐stained skin from Flgft/ft (right) and wild‐type mice (left). 20x original magnification. (F) Frequencies 
of indicated cell types isolated from ear skin of wild‐type (black bars) and Flgft/ft mice (red bars) and analyzed by flow cytometry. Bars show 
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microbial diversity with pronounced overrepresentation of fir‐
micutes (Figure 2B), including Staphylococcus species (Figure 2C). 
Strikingly, Flgft/ft mice raised in germ‐free (GF) conditions developed 
marked skin inflammation as neonates (Figure 2D,E) that resolved in 
adults (Figure 2F,G). Consistent with the lack of evident pathology 
in adult GF mice, serum IgE was reduced to WT level (Figure 2H). 
Expression of genes associated with AD (Il33, Il1a, Il1b) was signifi‐
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while Il33 and Il1a were downregulated independent of filaggrin de‐
ficiency, Il1b was significantly increased in the skin of 12‐week‐old 
adult Flgft/ft mice. Il1b expression was restored to WT levels when 
mice were kept under germ‐free conditions (Figure 2I). Similarly, 
treatment of pregnant Flgft/ft females and their litters with broad‐
spectrum antibiotics (ABX) from day E14 to P21 significantly de‐
creased clinical severity of skin inflammation in adult offspring at 
12 weeks of age (Figure S1A). In contrast, when adult 8‐9‐week‐
old Flgft/ft mice that had already developed skin inflammation were 
treated with ABX for 4 weeks, there was no amelioration of der‐
matitis (Figure S1B). These data indicate that the development of 
AD‐like skin inflammation in Flgft/ft mice is microbe‐mediated in 
neonatal stages, while in adult animals—once skin inflammation 
is established—antibiotic intervention cannot alter skin disease. 
However, the cellular events leading up to AD development in this 
mouse model remain unclear.
3.3 | Atopic dermatitis is independent of group 2 
innate lymphoid cells
The appearance and severity of dermatitis in Flgft/ft mice is dependent 
on cells of the innate immune system (Figure 3A)11 with a significant 
increase in dermal ILC2 numbers in Flgft/ft mice (Figure 1F). Therefore, 
we tested whether ILC‐deficient mice on Flgft/ft background devel‐
oped AD. Treatment of Rag1−/−Flgft/ft mice with anti‐CD90 mAb to 
deplete ILC2 did not alter development of skin inflammation (data 
not shown). Rag2−/−Il2rg−/−Flgft/ft mice developed skin inflammation 
comparable to Flgft/ft mice and Rag2−/−Flgft/ft mice (Figure 3B). As 
Rag2−/−Il2rg−/− are not only deficient in ILC but also NK, T, and B cells, 
we wanted to confirm our results by using a more specific model of 
ILC deficiency. Therefore, ILC2‐deficient Rorafl/sgIl7raCre/+ mice23 
were crossed onto the Flgft/ft background. ILC2‐deficient Flgft/ft mice 
developed severe skin inflammation (Figure 3C). These data from 
three separate and distinct models of ILC2 deficiency led us to con‐
clude that ILC2 were dispensable for skin inflammation in this spon‐
taneous and chronic model of AD‐like inflammation in mice with a 
defective skin barrier.
3.4 | Group 2 innate lymphoid cells promote acute 
skin inflammation
Daily application of MC903 elicits acute AD‐like skin inflamma‐
tion28 (Figure 3D). We, and others, have previously shown using 
antibody‐mediated depletion models as well as bone marrow chi‐
meric mice that development of MC903‐elicited skin inflammation is 
dependent on ILC2.25,27 Indeed, using ILC2‐deficient Rorafl/sgIl7raCre/+ 
mice, we could confirm that ear swelling was ameliorated in acute 
dermatitis (Figure 3D). As expected, ILC2 were not present in the 
inflamed skin of Rorafl/sgIl7raCre/+ mice (Figure 3E). Moreover, cellular 
infiltration was blunted in ILC2‐deficient mice including the recruit‐
ment of granulocytes, Th2 and Th17 cells (Figure 3E,F). Furthermore, 
type 2‐associated cytokine production in draining LN was impaired 
(Figure 3G). Because of the divergent roles ILC2 play in the initia‐
tion processes of acute chronic dermatitis, we sought to determine 
which other factors promote AD in the clinically more relevant 
Flgft/ft model.
3.5 | Impaired skin barrier–induced dermatitis 
operates independently of type 2 and type 
17 cytokines
Atopic dermatitis in humans is generally accompanied by an in‐
crease in type 2‐ and type 17‐associated cytokines,61‐63 with 
IL‐13 and IL‐5 reported as important systemic biomarkers for in‐
fant AD.64 Indeed, analysis of cytokines in the skin of Flgft/ft mice 
revealed a significant increase of IL‐4, IL‐5, IL‐9, IL‐13, IL‐17A, and 
IL‐22 (Figure 4A,B). To investigate whether the development of AD‐
like inflammation in Flgft/ft mice was dependent on the cardinal type 
2 cytokines, we generated IL‐4‐, IL‐5‐, IL‐9‐, and IL‐13‐knockout 
mice on the Flgft/ft background. However, Th2 cytokine‐deficient 
Flgft/ft mice developed inflammation comparable to that observed 
in cytokine‐sufficient Flgft/ft mice (Figure 4C). Similarly, knockout 
of IL‐17A or IL‐22 on the Flgft/ft background did not ameliorate skin 
inflammation (Figure 4D). Because neither knockout of individual 
type 2 nor type 17 cytokines protected from skin inflammation, we 
investigated cytokines upstream in the inflammatory cascade.
3.6 | Inflammasome‐independent IL‐1β‐mediated 
IL‐1R1 signaling is required for inflammation
IL‐1β is significantly elevated in skin blisters of patients with AD 
that have FLG mutations (Figure 5A) and in the skin of Flgft/ft mice 
(Figure 5B). We crossed Il1a−/−, Il1b−/−, and Il1r1−/− mice onto the Flgft/ft 
background to investigate their contribution to spontaneous skin 
inflammation (Figure 5C,D). While IL‐1α deficiency did not decrease 
the inflammatory score of Flgft/ft mice (P = 0.942), IL‐1β‐deficient 
F I G U R E  2   Pathogenic cutaneous microbiome promotes chronic inflammation in Flgft/ft mice. A, Principal component analysis of 
microbiome samples isolated from skin swaps of wild‐type (blue triangles) and Flgft/ft mice (green circles). Non‐lesional ear skin was swabbed 
at 12 wk (upper panel) and 3‐4 d (lower panel) of age. B,C, Mean relative abundance of bacterial phyla (B) and genera (C) of bacteria 
colonizing the skin of adult wild‐type and Flgft/ft mice. D, Representative photographs of neonatal Flgft/ft mice in a specific pathogen‐free 
(SPF, left panels) or germ‐free (GF, right panels) environment. E, Macroscopic scores for edema, erythema, scaling, hyperlinearity, and 
annular tail constrictions in neonatal SPF (black) and GF (red) Flgft/ft mice. Bar graphs show the mean + SEM of 9 mice per group. ns, not 
significant; *P < 0.05, ***P < 0.001. F, Photograph of adult Flgft/ft raised in an SPF (left) or GF (right) environment. Representative of 9 mice 
per group. G, Macroscopic scoring of SPF (black) and GF (red) Flgft/ft adult mice. ***P < 0.001. H, Serum IgE concentrations in SPF WT (open 
circles), SPF Flgft/ft (red), and GF Flgft/ft (black) adult mice. I, Relative quantification of Il33, Il1a, Il1b in the skin of adult WT (open circles) and 
adult Flgft/ft mice raised under SPF (red) or GF (black) conditions. Bars show the mean + SEM of 6 mice per group
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Flgft/ft mice were protected from the development of skin inflam‐
mation (Figure 5C,D; P = 0.013). Importantly, IL‐1R1 was required 
for IL‐1β‐mediated inflammation as Flgft/ft mice deficient in IL‐1R1 
were comparably protected (Figure 5C,D; P = 0.009). Furthermore, 
inhibition of IL‐1β by treatment with anti‐IL‐1β‐antibodies amelio‐
rated MC903 elicited acute exacerbation of skin disease in Flgft/ft 
mice (Figure 5E,F). We addressed contribution of other IL‐1 cytokine 
family members to spontaneous skin inflammation in Flgft/ft mice but 
development of dermatitis in Flgft/ft mice was independent of IL‐33, 
IL‐18, and IL‐36 (Figure S2A). These results reveal an important role 
for IL‐1β and IL‐1R1 in the development of spontaneous skin inflam‐
mation in this model.
F I G U R E  3   Dermatitis in Flgft/ft mice is independent of ILC2, while acute skin inflammation is ILC2‐dependent. A, Representative 
photographs of Rag−/−Flgft/ft (upper panel) and Rag2−/−Il2rg−/−Flgft/ft (lower panel) mice. B, Macroscopic clinical scoring of Flgft/ft (red), 
Rag2−/−Flgft/ft (black), and Rag2−/−Il2rg−/−Flgft/ft (blue). Graph shows the mean ± SEM from 6 to 7 mice per group. C, Macroscopic clinical 
scoring of wild‐type (dashed black), Rorafl/flFlgft/ft (red), and Rorafl/sgIl7rCre/+Flgft/ft (blue) mice. Graph shows the mean + SEM from 9 mice 
per group. D, Skin inflammation was induced in Rorafl/sgIl7rCre/+ (cko; red line) and control (WT; black line) mice by daily topical application 
of 4 nmol MC903 in 100% ethanol onto the right ear. The left ear was treated with ethanol and served as internal control. Ear thickness 
was measured daily. Mean ± SEM from at least 6 mice per group from two independent experiments is depicted. *P < 0.05, t test of AUC. 
E, Frequency of ILC2, mast cells, neutrophils, and eosinophils isolated from the ears of MC903‐ (blue) and ethanol‐treated (Vehicle, gray) 
Rorafl/sgIl7rCre/+ (cko) and control (WT) mice. F, Frequency of T helper cell subsets isolated from the ears of MC903‐ (blue) and ethanol‐
treated (gray) Rorafl/sgIl7rCre/+ (cko) and control (WT) mice. Bar graphs show the mean ± SEM from six mice of two independent experiments. 
*P < 0.05. G, Draining (MC903, blue) and non‐draining (Vehicle, gray) lymph node cells were restimulated with anti‐CD3/anti‐CD28 for 72 h 
and indicated cytokines in the supernatant were measured by ELISA. Bar graphs show the mean + SEM from 6 to 8 mice per group from two 
independent experiments. ns, not significant, t test of AUC
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IL‐1β requires processing by the NLRP3 inflammasome to be 
cleaved from pro‐IL‐1β to become bioactive IL‐1β. We generated 
Nlrp3−/−Flgft/ft mice to investigate the contribution of the NLRP3 in‐
flammasome to inflammation in our model (Figure 5G,H). However, 
inflammasome‐mediated maturation was not required as these 
mice developed skin inflammation comparable to that seen in Flgft/
ft mice (Figure 5G,H). NLRP3 deficiency did not alter the defective 
skin barrier or generation of IgE in mutant mice (Figure 5I,J). Indeed, 
there was also no role for ASC and AIM2 (Figure 5K). We further 
addressed whether inflammation in Flgft/ft mice can be targeted 
therapeutically with the potent inflammasome inhibitor MCC95065 
during a period of MC903‐induced exacerbation of skin inflamma‐
tion. Chemical inhibition of the inflammasome did not ameliorate the 
acute development of skin inflammation in Flgft/ft mice (Figure S2B), 
which was consistent with our results on spontaneous and chronic 
inflammation in Nlrp3−/−Flgft/ft mice. These data demonstrate the de‐
velopment of skin inflammation in mutant mice is independent of the 
NLRP3 inflammasome.
3.7 | Dermal mast cells promote inflammation in 
mice with impaired skin barrier
A study in mice with NLRP3‐dependent skin inflammation ana‐
lyzed the interplay between microbiota, TNFα, and IL‐1β and 
demonstrated a critical role for mast cells in skin inflammation.66 
Histological analysis of the skin of adult Flgft/ft mice showed elevated 
numbers of connective tissue mast cells (Figure 6A,B). As we ob‐
served significant amelioration in response to IL‐1β deficiency, we 
were interested whether IL‐1β was directly promoting mast cell 
activation and inflammation in Flgft/ft mice. Therefore, we generated 
bone marrow–derived mast cells from wild‐type and Il1r1−/− donors 
and stimulated them through FcεRI in the presence and absence of 
IL‐1β costimulation (Figure 6C). While FcεRI‐crosslinking induced 
the release of pro‐inflammatory IL‐6 and TNFα, as well as CCL2 and 
IL‐13, costimulation with IL‐1β further increased cytokine release in 
an IL‐1R1‐dependent manner (Figure 6C). This result suggests a hy‐
perresponsive phenotype of mast cells and a pro‐inflammatory role 
in dermatitis exacerbation in response to IL‐1β.
In order to confirm the pathogenic role of IL‐1β‐responsive mast 
cells in skin inflammation, we transferred wild type‐ or Il1r1−/−‐de‐
rived BMMC into the ears of mast cell–deficient KitW‐sh mice67 on 
a Flgft/ft background (Figure 6D). Indeed, when we induced inflam‐
mation in these mice using MC903, IL‐1β‐responsive mast cells 
were sufficient to aggravate inflammation (Figure 6D). Interestingly, 
germ‐free Flgft/ft mice had significantly decreased serum levels of 
IgE compared to their SPF counterparts (Figure 2H) and—lacking the 
IgE‐mediated activation of mast cells—also showed decreased lev‐
els of MCP‐1 (Figure 6F). Importantly, GF mice showed reduced ex‐
pression of IL‐1β further reducing activation of mast cells (Figure 2I). 
These data indicate that IL‐1β‐mediated hyperactivation of mast 
cells contributes significantly to dermatitis in Flgft/ft mice.
4  | DISCUSSION
In the present study, we have shown that the development of skin 
inflammation in Flgft/ft mice is independent of group 2 innate lym‐
phoid cells but requires an interplay between the microbiome, IL‐1β, 
F I G U R E  4   Dermatitis in Flgft/ft mice is independent of type 2‐ and type 17‐associated effector cytokines. A,B, Indicated cytokines 
isolated from ear skin of age‐matched wild type (open bars) and Flgft/ft (red bars) depicted as pg cytokine per mg of total isolated protein. 
C, Macroscopic clinical scoring of wild‐type (dashed black), Flgft/ft (red), IL‐4−/−Flgft/ft (black), IL‐5−/−Flgft/ft (orange), IL‐9−/−Flgft/ft (violet), and 
IL‐13−/−Flgft/ft (blue) mice. Graph shows the mean + SEM from at least 8 mice per group. D, Macroscopic clinical scoring of wild‐type (dashed 
black), Flgft/ft (red), IL‐17A−/−Flgft/ft (green), and IL‐22−/−Flgft/ft (violet) mice. Graph shows the mean + SEM from at least 6 mice per group from 
two to three independent experiments
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F I G U R E  5   Inflammation in Flgft/ft mice 
is dependent on IL‐1β and IL‐1R1 signaling 
but occurs inflammasome‐independent. 
A, IL‐1β was measured in skin biopsies of 
patients with or without FLG mutation. 
B, IL‐1β protein concentration in ear 
skin of age‐matched wild type (open 
bars) and Flgft/ft (red bars) depicted as 
pg cytokine per mg of total isolated 
protein. C, Representative photographs 
of Flgft/ft (upper left), IL‐1α−/−Flgft/ft 
(upper right), IL‐1β−/−Flgft/ft (lower left), 
and IL‐1R1−/−Flgft/ft (lower right). D, 
Macroscopic clinical scoring of wild‐type 
(open circles), Flgft/ft (red), IL‐1R1−/−Flgft/ft  
(black), IL‐1β−/−Flgft/ft (light blue), and 
IL‐1α−/−Flgft/ft (blue) mice. Graph shows 
the mean + SEM from 8 mice per group. 
*P < 0.05; **P < 0.01; t test of AUC against 
Flgft/ft. E, Flgft/ft mice were treated daily 
with isotype control mAb (gray circles), 
anti‐IL‐1α‐(blue) or anti‐IL‐1β‐mAb (red) 
and MC903 was topically applied to 
induce dermatitis exacerbation. Ear 
thickness was measured daily. Graph 
shows the mean + SD of 4‐5 mice per 
group. *P < 0.05, AUC. F, Representative 
H&E‐stained sections of untreated (left) 
and MC903‐treated ears from (E). G, 
Representative photographs of Flgft/ft 
(upper panel) and Nlrp3−/−Flgft/ft (lower 
panel) mice. H, Macroscopic clinical 
scoring of wild‐type (open circles), Flgft/ft  
(red), and Nlrp3−/−Flgft/ft (black) mice. 
Graph shows the mean + SEM from 7 mice 
per group. I, Serum IgE levels in Flgft/ft  
(red), and Nlrp3−/−Flgft/ft (black) mice. J, 
Transepidermal water loss in wild‐type 
(gray), Nlrp3−/− (dark gray), Flgft/ft (red), 
and Nlrp3−/−Flgft/ft (black) mice. Bar graphs 
show the mean + SEM from 4 to 6 mice 
per group. K, Macroscopic clinical scoring 
of wild‐type (open circles), Flgft/ft (red), 
Aim−/−Flgft/ft (blue), and Asc−/−Flgft/ft (black) 
mice. Graph shows the mean + SEM 
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and mast cells. ILC2 are implicated in AD, with AD skin lesions show‐
ing higher expression of ILC2 genes RORA, IL1R1, IL17RB, TSLPR, 
and AREG, and increased numbers of ILC2.25,27 We have reported 
elevated ILC2 in skin blisters of AD patients with mutation in FLG.11 
Here, mice deficient in ILC2 developed significantly ameliorated 
acute skin inflammation but despite the higher numbers of ILC2 
present in the skin of Flgft/ft mice,11 ILC2 play a redundant role in 
the pathogenesis of chronic dermatitis. While MC903‐induced ILC2 
function could be targeted by anti‐IL‐18,68 we show that chronic in‐
flammation is independent of IL‐18, further corroborating the ob‐
served redundancy of ILC2.69,70 Although ILC2 may contribute to 
genesis of acute skin inflammation, their increase in numbers under 
chronic inflammatory conditions is probably a consequence of an 
overall increase in infiltrating immune cell populations.
A similar general increase of type 2‐ and 17‐associated cytokine 
production is observed in the inflamed skin of Flgft/ft mice; however, 
no functional roles for individual cytokines were observed in mutant 
mice. This is perhaps surprising as IL‐4 and IL‐13 are known to be 
involved upstream of filaggrin in the development of AD by promot‐
ing skin barrier disintegration71,72 and dermal fibrosis73—possibly via 
TSLP.74 IL‐5 and IL‐9 are effector cytokines promoting single aspects 
of AD, such as eosinophilia,56 neuronal stimulation,75 and survival of 
T cells and ILC2.76 IL‐17A can promote skin inflammation77 and was 
shown to decrease expression of filaggrin and tight junction pro‐
teins.78 Similarly, IL‐22 is able to regulate keratinocyte function.63,79 
Despite these cytokines being upregulated in the skin, the single 
knockout of each cytokine did not alleviate disease. This highlights 
that single target therapy may not be useful to therapeutically de‐
plete cytokines during chronic disease. In this context, dupilumab, 
targeting the IL‐4Rα‐chain and thereby the actions of IL‐4 and IL‐13, 
has recently been approved by the FDA for the treatment of mod‐
erate‐to‐severe AD patients (reviewed in80) and is proving to be ef‐
ficacious.81,82 Interestingly, in the context of this study, in patients 
undergoing dupilumab treatment IL‐1β was shown to be consider‐
ably downregulated,83 while markers of skin integrity, including FLG, 
are restored.84
We show that chronic dermatitis in Flgft/ft mice developed inde‐
pendently of IL‐1α but was instead dependent on IL‐1β. Importantly, 
treatment with anti‐IL‐1β ‐antibody could alleviate MC903‐induced 
skin flares supporting findings that canakinumab can prevent TSLP 
release from keratinocytes.85 In a recent study, it was shown that 
6‐8‐week‐old Flgft/ft mice without overt dermatitis constitutively 
F I G U R E  6   IL‐1β drives hyperactivation of mast cells in AD‐like 
inflammation. A, Toluidine blue staining of wild‐type (upper panel) 
and Flgft/ft (lower panel) skin. Red arrows indicate connective tissue 
mast cells. B, Quantification of mast cells per HPF from toluidine 
blue stained skin samples. Bar graphs show the mean + SEM from 
8 mice per group. *P < 0.05, t test. D, Bone marrow–derived mast 
cells from wild‐type (left) and Il1r1−/− (right) mice were stimulated 
with media (light gray) or plate‐bound anti‐FcεRIα (10 µg/mL) in the 
presence (red) or absence (blue) of recombinant IL‐1β (10 ng/mL). 
CCL2, IL‐6, IL‐13, and TNFα were measured by ELISA. Bars show the 
mean + SEM of nine replicates from three independent experiments. 
*P < 0.05. E, Wild‐type (black) and IL‐R1−/− (blue) mast cells were 
transferred intradermally into the ears of KitW‐shFlgft/ft mice. Six 
weeks later, MC903 or 100 EtOH was applied onto the ears and ear 
thickness was measured daily. Graph shows the mean + SEM of 5 
mice per group from two experiments. *P < 0.05, t test of AUC.  
F, Serum mast cell protease 1 levels from adult (10 wk) wild‐type 
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expressed increased amounts of IL‐1α in the epidermis but 21 days 
after acute mechanical skin injury released less IL‐1α and more 
IL‐1β.86 These results indicate important, but divergent, roles for IL‐1 
family cytokines in acute and chronic dermatitis. One of our next 
steps will therefore include the analysis what impact IL‐1‐family 
members have on expression of key skin barrier proteins.
In Flgft/ft mice, we observed that IL‐1β enhances FcεRI‐me‐
diated signaling in mast cells confirming previous reports.87 
Recently, it was shown that mast cells with a mutated NLRP3 
inflammasome and higher caspase‐1 activity produced IL‐1β in 
response to TNFα or LPS stimulation.66 Using kitw‐shFlgft/ft mice as 
mast cell–recipient mice, we show that IL‐1β‐responsive mast cells 
promote inflammation via IL‐1R1‐signaling. Because kitw‐sh mice 
certainly have phenotypes independent of mast cell deficiency,88 
further studies using more sophisticated models of mast cell defi‐
ciency are required to analyze their in vivo function in mice with 
skin barrier defects.
Treatment with the NLRP3‐inflammasome inhibitor MCC950 
did not ameliorate inflammation in our multifactorial model of AD 
when we triggered an acute inflammatory response with MC903. 
Furthermore, inflammation was unaltered in NLRP3‐deficient, ASC‐
deficient, and AIM2‐deficient Flgft/ft mice. Therefore, IL‐1β process‐
ing occurs independent of the NLRP1, NLRP3, NLRP6, and AIM2 
inflammasome. To date, we cannot rule out a role for the NLRC4 
inflammasome (or NAIP‐NLRC4) that can directly recruit caspase‐1. 
In a recent study, NLRC4 was found in the scale extracts of psoriasis 
patients; however, no inflammasome components (including NLRC4) 
were found in atopic dermatitis patients.89 Inflammasome‐indepen‐
dent processing of IL‐1β has been observed in a variety of settings 
(reviewed in90). In particular, neutrophil‐ and mast cell–derived pro‐
teases play prominent roles in the extracellular processing of IL‐1‐
family cytokines,91,92 with human mast cell protease 1 shown to 
process pro‐IL‐1.93 Increased mast cell chymase activity may there‐
fore contribute to IL‐1β maturation in the Flgft/ft model; however, fur‐
ther investigations are required to fully understand the role of mast 
cell proteases in AD.
Skin microbiome sequencing revealed a shift toward patho‐
genic staphylococci, which has been reported in AD patients.30 
While the microbiota in flaky tail mice induced IL‐17A‐mediated 
neutrophilia, we could show that in Flgft/ft mice IL‐17A was re‐
dundant.33 Indeed, IL‐17A‐mediated inflammation is observed in 
Tmem79ft/ft (Saunders et al, unpublished) but not in Flgft/ft mice. 
Our results indicate that the pathogenic microbiome present in 
neonates imprinted a hyperresponsive phenotype in mast cells. 
This phenotype is maintained when adult mice were treated with 
antibiotics. When we treated neonate Flgft/ft mice with antibiot‐
ics before inflammation is established, or when mice are raised 
in GF conditions, the subsequent adult dermatitis phenotype is 
significantly ameliorated. A recent study in a cohort of newborn 
children suggests that early colonization with commensal staph‐
ylococci genera protects from AD and that microbiotic changes 
only occur after the onset of AD.94 Therefore, the Flgft/ft mouse 
model provides a basis for future investigations into the extrinsic 
factors and intrinsic mechanisms of neonatal inflammation be‐
fore AD‐like inflammation develops. While the broad application 
of state‐of‐the‐art techniques gives a comprehensive analysis 
of the AD‐like inflammation in mutant mice on the Flgft/ft back‐
ground, future approaches need to target the separate path‐
ways leading to disease and untangle the relative contribution 
to pathogenesis.
In summary, we revealed a critical role of IL‐1β in the initiation 
and maintenance of skin inflammation in a mutant mouse model of 
defective skin barrier. Further investigations will be required to as‐
sess the contribution of IL‐1β‐responsive mast cells, as well as roles 
of the integrity of the skin barrier and interplay of the microbiome, in 
the generation of inflammation in AD patients. These endeavors will 
lead to the development of novel management options for children 
suffering from AD.
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